HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com.
HiFiBiO Therapeutics has operations in Paris, France, Cambridge, MA, USA and Hangzhou, China.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $179.5M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | B Capital ... | b.capital/ |
| - | B Capital ... | bcapgroup.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 22.06.2021 | Series D | $75M | IDG Capita... |
| 29.08.2019 | Series C | $67M | - |
| 18.05.2018 | Series B | $37.5M | - |
Mentions in press and media 21
| Date | Title | Description |
| 09.01.2023 | HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 | HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel mon... |
| 15.06.2021 | HiFiBiO Therapeutics secures $75M | HiFiBiO Therapeutics has raised $75 million in a Series D led by Mirae Asset Financial Group. Founded in 2013, the company is a developer of single-cell profiling technologies designed to accelerate biotherapeutics that combat cancer and au... |
| 15.06.2021 | SoftBank Vision Fund 2 builds momentum | IRL, a Gen-Z-focused messaging app maker with just 25 employees, became a unicorn on Tuesday. It’s an enormous valuation for a company with so few workers. But IRL’s attainment of unicorn status had been anticipated for a while. New social ... |
| 15.06.2021 | China’s HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group | HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean gl... |
| 15.06.2021 | China’s HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group | Premium HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a K... |
| 15.06.2021 | SoftBank ramps up its unicorn bets in 2021, taking a social media company to $1 billion | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. IRL, a Gen-Z-focused messaging app maker with just 25 employees, became a unicorn on Tuesday. It’... |
| 14.06.2021 | HiFiBiO Therapeutics Closes $75M Series D | CAMBRIDGE, MA, HiFiBiO Therapeutics announced the completion of an oversubscribed $75M Series D financing round led by Mirae Asset Financial Group. >> Click here for more funding data on HiFiBiO Therapeutics >> To export HiF... |
| 14.06.2021 | HiFiBiO Therapeutics : Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic | HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, today announced the completion of an oversubscribed $75M Series D financing round. The funding was led by t... |
| 14.06.2021 | HiFiBiO Therapeutics Closes $75M Series D Financing | HiFiBiO Therapeutics, a Cambridge, Massachusetts-based multinational biotechnology company with expertise in immune modulation and drug intelligent science, closed a $75M Series D financing round. The round was led by the new investor Mirae... |
| 29.08.2019 | IDG Capital leads $67m Series C in biotech firm HiFiBio Therapeutics | Premium HiFiBio Therapeutics, an emerging multinational biotherapeutics company based in France, has raised $67 million in its Series C funding round led by new investor IDG Capital with participation from existing shareholder Sequoia Capit... |
Show more